Gilead Sciences Inc. has initiated a significant expansion with a groundbreaking ceremony for a new manufacturing and technical development site in the Bay Area. This facility is part of Gilead's ambitious $32 billion investment commitment in the United States, aimed at delivering next-generation therapies and fostering U.S. leadership in global biopharma innovation. The expansion includes the development of two additional state-of-the-art facilities at Gilead's Foster City headquarters: a new research building to accelerate scientific discovery and a biologics manufacturing facility to enhance domestic production capacity. These projects are expected to create thousands of American jobs and contribute significantly to the U.S. economy by generating an estimated $43 billion in economic value. Gilead's efforts underscore its role as a major player in the biopharmaceutical industry and its dedication to advancing human health globally.